Skip to main content
Skip to footer content
Clinical Trial Phase I “Safety and Tolerability of Escalating Doses of Subcutaneous Elafin (Tiprelestat) Injection in Healthy Normal Subjects” completed.
tiakis (formerly Proteo Biotech AG) Elafin Enters the Clinic For Subcutaneous Use In Pulmonary Arterial Hypertension
tiakis receives GLP Certificate from Competent Authority
New mechanism of Elafin to prevent lung injury in mechanically ventilated newborns